Chemotherapy-related and late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?
Chemotherapy-related and late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors?
复制标题
DOI：
10.1038/sj.leu.2400769
复制
发表时间：
1997-09-01
期刊：
影响因子：
11.4
通讯作者：
Johansson, B
中科院分区：
文献类型：
--
作者：
PedersenBjergaard, J;BrondumNielsen, K;Johansson, B
DNA拓扑异构酶II抑制剂治疗已被证明会导致急性髓性白血病（AML）的风险增加，通常会出现染色体带11 q23和21 q22的平衡易位。此外，在治疗相关AML（t-AML）中更罕见的其他平衡畸变，如t（15;17）和inv（16）也与这些药物相关。最近，我们观察了一例慢性粒细胞白血病（CML）患者，在用足叶乙甙、顺铂和博莱霉素治疗生殖细胞肿瘤后出现t（9;22）。基于这个病例和文献中对化疗相关的t（9;22）白血病的回顾，我们认为DNA拓扑异构酶II抑制剂治疗与携带费城染色体的各种类型白血病的发生之间存在因果关系。
Therapy with DNA topoisomerase II inhibitors has been shown to result in an increased risk of acute myeloid leukemia (AML), often presenting balanced translocations to chromosome bands 11q23 and 21q22. Also other balanced aberrations, more rarely observed in therapy-related AML (t-AML), such as t(15;17) and inv(16) have been associated with these drugs. Recently we observed a case of chronic myeloid leukemia (CML) with t(9;22) after therapy of a germ cell tumor with etoposide, cisplatin and bleomycin. Based on this case and a review of chemotherapy-related leukemias with t(9;22) from the literature, we suggest a causal relationship between therapy with DNA topoisomerase II inhibitors and development of various types of leukemia carrying the Philadelphia chromosome.